Vigmed granted an additional patent for CLiP®

The Swedish Patent and Registration Office (PRV) has announced to Vigmed that it
intends to grant the Company an additional patent for their needle protecting
solution CLiP®.
Vigmed has earlier been granted patent for the needle protecting solution CLiP®,
and I.V. systems comprising CLiP®. This patent will broaden Vigmed’s scope of
protection, since it gives Vigmed protection for another feature of CLiP®, and
regardless of field of application. An international patent application is also
filed.

Vigmed has filed nationally and internationally more than 60 patents and patent
applications based on three innovation platforms. The company owns all its
patents and patent applications without any restrictions. The basic patents all
have a maximum validity period.

Vigmeds strategy is to protect the Company's technology and products in all
geographical areas deemed to be of importance. Vigmed intends to expand its
patent portfolio continuously on both the offensive and defensive patent and
utility model rights based on a number of new innovation platforms.
For further information contact:

Chairman of the board, Lennart Holm +46 70 630 8562 or CEO, Finn Ketler +46 42
600 5311
Vigmed is a Swedish medical technology company whose mission is to eliminate
needlestick injuries by offering the market unique needle-protected products.
Vigmed is headquartered in Helsingborg, Sweden, and has approximately 20
employees. Vigmed’s share is traded on NASDAQ OMX First North in Stockholm
(ticker VIG) and has approximately 5 400 shareholders. Remium Nordic AB is the
Company’s Certified Advisor.

Additional information such as company description, a video presentation and
risk factors can be found on Vigmed’s website: www.vigmed.com/investor